|Time Commitment:||4.5 hours|
|Target Professions:||MD, Nurse Practitioner, Nurse, Physician Assistant, DO|
|Target Specialties:||Hematology, Hematology/Oncology, Oncology|
|Credits Available:||4.50 AMA PRA Category 1 Credit™, Maintenance of Certification (MOC) points available|
Welcome to our interactive and engaging educational initiative on managing anemia in myelodysplastic syndromes (MDS). Anemia is a common issue in MDS, causing symptoms like fatigue, pallor, shortness of breath, and light-headedness. It can have a significant impact on patients' quality of life and lead to complications such as iron overload and red blood cell transfusion dependence. Moreover, anemia and transfusion dependence are associated with poor outcomes in MDS. In this program, you will learn the optimal time to initiate anemia treatment, how best to dose luspatercept and address adverse events, and familiarize yourself with emerging data in the treatment of anemia related to low-risk MDS to better help your patients.
This course is designed to provide healthcare professionals with a comprehensive understanding of anemia in the context of myelodysplastic syndrome (MDS) and equip them with the knowledge and skills necessary for effective management
This course is designed to provide healthcare professionals with a comprehensive understanding of anemia in the context of myelodysplastic syndrome (MDS) and equip them with the knowledge and skills necessary for effective management.
This module covers anemia treatment due to MDS.
This module covers the treatment of anemia in MDS with a focus on luspatercept.
In this last activity, you will evaluate several case-based scenarios now that you have completed the educational modules.
Considering the multi-faceted nature of MDS, let's explore the challenges and opportunities in managing this complex condition. Reflecting on your experiences & understanding of MDS, what do you think is most compelling and concerning?
In this second group discussion, we will reflect on what we have learned and discuss best practices, implications of emerging data, and strategies to optimize patient outcomes.
Meet Richard, a 67-year-old man who has been diagnosed with low-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS).
Let's consider personal, practice, and system-based changes you can implement to improve outcomes for your patients with Myelodysplastic Syndromes (MDS)